August 28, 2007
Our STN: BL 125245/0
Roche Molecular Systems, Inc.
Attn: Ms. Lesley Farrington
4300 Hacienda Drive
P.O. Box 9002
Pleasanton, CA 94566-0990
Dear Ms. Farrington:
We have approved your biologics license application for cobas TaqScreen West Nile Virus Test for use on the cobas s 201 system effective this date. You are hereby authorized to introduce or deliver for introduction into interstate commerce, the cobas TaqScreen West Nile Virus Test for use on the cobas s 201 system under your existing Department of Health and Human Services U.S. License No. 1636. The cobas TaqScreen West Nile Virus Test for use on the cobas s 201 system is indicated for the qualitative detection of West Nile Virus (WNV) RNA in plasma specimens from individual human donors, donors of whole blood and blood components, and other living donors. It is also intended for use in testing plasma specimens to screen organ donors when specimens are obtained while the donor's heart is still beating. This assay is not intended for use on samples of cord blood.
The assay is intended for use in testing of individual donor samples. It is also intended for use in testing pools of human plasma comprised of equal aliquots of not more than 6 individual donations from volunteer donors of whole blood and blood components. This assay is not intended for use as an aid in the diagnosis of West Nile Virus infection.
Under this authorization, you are approved to manufacture the cobas TaqScreen West Nile Virus Test for use on the cobas s 201 system at your facility in Somerville, New Jersey. You must label your product with the proprietary name cobas TaqScreen West Nile Virus Test for use on the cobas s 201 system.
Please submit final container samples of the product and each kit component in final containers together with protocols showing results of all applicable tests. You may not distribute any lots of product until you receive a notification of release from the Director, Center for Biologics Evaluation and Research (CBER).
You must submit information to your biologics license application for our review and written approval under 21 CFR 601.12 for any changes in the manufacturing, testing, packaging or labeling of the cobas TaqScreen West Nile Virus Test for use on the cobas s 201 system, or in the manufacturing facilities.
Submit adverse experience reports in accordance with the Medical Device Reporting requirements for medical devices (21 CFR 803) as required by (21 CFR 600.81(k)(2)). Since your product is characterized as a device as well as a biological, submit these reports to the MedWatch System using MedWatch Reporting Form 3500A. Required reports should be submitted to the Food and Drug Administration, Center for Devices and Radiological Health, Medical Device Reporting, P.O. Box 3002, Rockville, MD 20847-3002.
You must submit reports of biological product deviations under 21 CFR 600.14. You promptly should identify and investigate all manufacturing deviations, including those associated with processing, testing, packing, labeling, storage, holding and distribution. If the deviation involves a distributed product, may affect the safety, purity, or potency of the product, and meets the other criteria in the regulation, you must submit a report on Form FDA-3486 to the Director, Office of Compliance and Biologics Quality, Center for Biologics Evaluation and Research, HFM-600, 1401 Rockville Pike, Rockville, MD 20852-1448.
Please submit all final printed labeling at the time of use and include implementation information on FDA Form 356h and FDA Form 2567 as appropriate. Please provide a PDF-format electronic copy as well as original paper copies (ten for circulars and five for other labels). In addition, you may wish to submit two draft copies of the proposed introductory advertising and promotional labeling with an FDA Form 2253 to the Center for Biologics Evaluation and Research, Advertising and Promotional Labeling Branch, HFM-602, 1401 Rockville Pike, Rockville, MD 20852-1448. Two copies of final printed advertising and promotional labeling should be submitted at the time of initial dissemination, accompanied by a FDA Form 2253.
All promotional claims must be consistent with and not contrary to approved labeling. You should not make a comparative promotional claim or claim of superiority over other products unless you have submitted data to support such claims to us and had them approved.
--- signature ---
Jay S. Epstein, M.D.
Office of Blood Research and Review
Center for Biologics Evaluation and Research